Fei‐Ting Hsu
Impact in
- Rehabilitation top 2%
- Magnolia and Illicium research
- Cancer Research top 5%
Papers in
-
- Biological Activity of Diterpenoids and Biflavonoids 17
- Genomics, phytochemicals, and oxidative stress 6
- Oncology 19
- Co-authors
- I‐Tsang Chiang (37 shared papers)Yu‐Chang Liu (25 shared papers)Jing‐Gung Chung (20 shared papers)Jeng‐Jong Hwang (11 shared papers)Po–Jung Pan (6 shared papers)Cheng‐Yu Chen (10 shared papers)Jiann‐Hwa Chen (8 shared papers)SONG-SHEI LIN (6 shared papers)
- Journals
- Anticancer Research (25 papers)Cancer Research (10 papers)Biomedicine & Pharmacotherapy (7 papers)Environmental Toxicology (6 papers)International Journal of Molecular Sciences (5 papers)
- Partner nations
- TaiwanUnited StatesSouth Korea
In The Last Decade
Fei‐Ting Hsu
121 papers receiving 2.2k citations
Peers
Comparison fields: 5 of 110
- Rehabilitation 161
- Cancer Research 306
- Genetics 154
- Molecular Biology 937
- Pharmacology 106
Countries citing papers authored by Fei‐Ting Hsu
This map shows the geographic impact of Fei‐Ting Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei‐Ting Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei‐Ting Hsu more than expected).
Fields of papers citing papers by Fei‐Ting Hsu
This network shows the impact of papers produced by Fei‐Ting Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei‐Ting Hsu. The network helps show where Fei‐Ting Hsu may publish in the future.
Co-authors
The 25 scholars most cited alongside Fei‐Ting Hsu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 126 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 225 | |
| 2 | 2022 | 79 | |
| 3 | 2016 | 58 | |
| 4 | Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells. | 2013 | 54 |
| 5 | 2016 | 54 | |
| 6 | 2014 | 51 | |
| 7 | 2016 | 43 | |
| 8 | 2019 | 42 | |
| 9 | 2018 | 41 | |
| 10 | 2010 | 39 | |
| 11 | 2020 | 39 | |
| 12 | 2020 | 37 | |
| 13 | 2019 | 36 | |
| 14 | 2015 | 35 | |
| 15 | 2019 | 33 | |
| 16 | 2019 | 33 | |
| 17 | 2014 | 33 | |
| 18 | 2020 | 32 | |
| 19 | 2018 | 32 | |
| 20 | 2017 | 32 |
About Fei‐Ting Hsu
Fei‐Ting Hsu is a scholar working on Molecular Biology, Oncology, Psychiatry and Mental health, Cancer Research and Rehabilitation, having authored 126 papers that have together received 2.2k indexed citations. Recurring topics across this work include Cancer, Stress, Anesthesia, and Immune Response (18 papers), Magnolia and Illicium research (18 papers), Biological Activity of Diterpenoids and Biflavonoids (17 papers), Cancer Mechanisms and Therapy (11 papers), NF-κB Signaling Pathways (10 papers), Bladder and Urothelial Cancer Treatments (6 papers), Macrophage Migration Inhibitory Factor (6 papers) and Genomics, phytochemicals, and oxidative stress (6 papers). The work is most often cited by research in Rehabilitation (161 citations), Cancer Research (306 citations), Genetics (154 citations), Molecular Biology (937 citations) and Pharmacology (106 citations). Fei‐Ting Hsu has collaborated with scholars based in Taiwan, United States and South Korea. Frequent co-authors include I‐Tsang Chiang, Yu‐Chang Liu, Jing‐Gung Chung, Jeng‐Jong Hwang, Po–Jung Pan, Cheng‐Yu Chen, Jiann‐Hwa Chen, SONG-SHEI LIN, Yu‐Chieh Jill Kao and Chia‐Feng Lu. Their work appears in journals such as Anticancer Research, Cancer Research, Biomedicine & Pharmacotherapy, Environmental Toxicology and International Journal of Molecular Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.